
Sign up to save your podcasts
Or
In this episode, Dr. Chauhan discusses many issues that impact NET patients, including COVID-19.
Dr. Aman Chauhan is board certified in internal medicine and specializes in the treatment of neuroendocrine tumors. He is a member of the medical oncology team at the UK Markey Cancer Center dedicated to multidisciplinary evaluation and treatment.
His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and non-small cell lung cancer. As Markey’s director of NET Theranostics, Dr. Chauhan will identify NET patients who qualify for Lutathera® (Lutetium 177 DOTATATE) treatments for gastroenteropancreatic neuroendocrine tumors.
3.8
44 ratings
In this episode, Dr. Chauhan discusses many issues that impact NET patients, including COVID-19.
Dr. Aman Chauhan is board certified in internal medicine and specializes in the treatment of neuroendocrine tumors. He is a member of the medical oncology team at the UK Markey Cancer Center dedicated to multidisciplinary evaluation and treatment.
His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and non-small cell lung cancer. As Markey’s director of NET Theranostics, Dr. Chauhan will identify NET patients who qualify for Lutathera® (Lutetium 177 DOTATATE) treatments for gastroenteropancreatic neuroendocrine tumors.
12 Listeners